medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-33-58-63medalphabet-2328Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYПатологический ангиогенез при псориазе и псориатическом артрите: патогенетическое значение и терапевтические перспективыPsoriasis and pathological angiogenesis: pathogenetic signifcance and therapeutic perspectiveshttps://orcid.org/0000-0001-6515-1924ПритулоО. А.PrituloO. A.

Притуло Ольга Александровна, д. м. н., проф., главный внештатный специалист-дерматовенеролог Минздрава Республики Крым, зав. кафедрой дерматовенерологии и косметологии

г. Симферополь, Республика Крым

Pritulo Olga A., DM Sci (habil.), professor, chief freelance specialistdermatovenerologist of the Ministry of Health of the Republic of Crimea, head of Dermatovenereology and Cosmetology Dept.

Simferopol, Crimea

https://orcid.org/0000-0003-4533-2415ПетровА. А.PetrovA. A.

Петров Алексей Андреевич, аспирант кафедры дерматовенерологии и косметологии

г. Симферополь, Республика Крым

Petrov Aleksey A., post-graduate student of Dept of Dermatovenereology and Cosmetology

Simferopol, Crimea

ya.alexey2312@yandex.ruИнститут «Медицинская академия имени С. И. Георгиевского» ФГАОУ ВО «Крымский федеральный университет имени В. И. Вернадского»РоссияMedical Academy n. a. S. I. Georgievsky of Crimean Federal University n. a. V. I. VernadskyRussian Federation202113122021033Ревматология в общей врачебной практике (2)5863Copyright © Притуло О.А., Петров А.А., 20212021Притуло О.А., Петров А.А.Pritulo O.A., Petrov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2328

В литературном обзоре представлены данные о роли патологического ангиогенеза в развитии псориаза и псориатического артрита. Ряд недавних исследований показали, что, кроме цитокинового дисбаланса и активации Т-клеточного звена иммунитета, важным патогенетическим звеном этих заболеваний является патологическая васкуляризация. Сосудистые изменения в дерме появляются раньше клинически видимых кожных проявлений и могут длительно сохраняться после лечения, так же, как и явления неоангиогенеза в синовиальной оболочке и энтезисах способствуют хронизации воспалительного процесса при псориатическом артрите. В работе представлен обзор современной литературы, посвященной главному регулятору ангиогенеза – фактору роста эндотелия сосудов, его роли в патогенезе псориаза и возможным терапевтическим перспективам.

The literature review presents data on the role of pathological angiogenesis in the development of psoriasis. Several recent studies have shown, in addition to cytokine imbalance and activation of the T-cell link of immunity, an important pathogenetic link is pathological vascularization. Vascular changes in the dermis appear before clinically visible skin manifestations and can persist for a long time after treatment, as well as the phenomena of neoangigenesis in the synovial membrane and enthesises contribute to the chronicization of inflammatory process in psoriatic arthritis. The article presents an overview of the modern literature on the main regulator of angiogenesis – vascular endothelial growth factor, its role in the pathogenesis of psoriasis and possible therapeutic prospects.

псориазпсориатический артритангиогенезфактор роста эндотелия сосудовpsoriasisangiogenesisvascular endothelial growth factorReferencesКубанов А.А., Карамова А.Э., Артамонова О.Г. Новые возможности в лечении псориаза и псориатического артрита. Научно-практическая ревматология. 2018; 56 (6): 722–726. https://doi.org/10.14412/1995–4484–2018–722–726Kubanov A.A., Karamova A.E., Artamonova O.G. New possibilities in the treatment of psoriasis and psoriatic arthritis. Scientifc and practical rheumatology. 2018; 56 (6): 722–726. https://doi.org/10.14412/1995–4484–2018–722–726Коротаева Т.В. Ангиогенез при псориазе и псориатическом артрите: клеточные и гуморальные механизмы, роль в патогенезе и поиск перспективных мишеней терапии. Современная ревматология. 2014; 8 (2): 71–75. https://doi.org/10.14412/1996–7012–2014–2–71–75T. V. Korotaeva Angiogenesis in psoriasis and psoriatic arthritis: cellular and humoral mechanisms, role in pathogenesis and search for promising targets for therapy. Modern rheumatology. 2014; 8 (2): 71–75. https://doi.org/10.14412/1996–7012–2014–2–71–75Weigle N., McBane S. Psoriasis. Am Fam Physician. 2013. 87 (9): 626–633.Weigle N., McBane S. Psoriasis. Am Fam Physician. 2013. 87 (9): 626–633.Kimball A.B., Leonardi C., Stahle M., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014; 171 (1): 137–147. https://doi.org/10.1111/bjd.13013Kimball A.B., Leonardi C., Stahle M., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014; 171 (1): 137–147. https://doi.org/10.1111/bjd.13013Elder J.T. Expanded Genome-Wide Association Study Meta-Analysis of Psoriasis Expands the Catalog of Common Psoriasis-Associated Variants. J Investig Dermatol Symp Proc. 2018 Dec; 19 (2): S77–S78. https://doi.org/10.1016/j.jisp.2018.09.005Elder J.T. Expanded Genome-Wide Association Study Meta-Analysis of Psoriasis Expands the Catalog of Common Psoriasis-Associated Variants. J Investig Dermatol Symp Proc. 2018 Dec; 19 (2): S77–S78. https://doi.org/10.1016/j.jisp.2018.09.005Gudjonsson J.E. et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis com- pared with Cw6 heterozygotes. Br. J. Dermatol. 2003; 148: 233–235. https://doi.org/10.1046/j.1365–2133.2003.05115.xGudjonsson J.E. et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis com- pared with Cw6 heterozygotes. Br. J. Dermatol. 2003; 148: 233–235. https://doi.org/10.1046/j.1365–2133.2003.05115.xCapon F. The Genetic Basis of Psoriasis. Int. J. Mol. Sci. 2017; 18: 2526. https://doi.org/10.3390/ijms18122526Capon F. The Genetic Basis of Psoriasis. Int. J. Mol. Sci. 2017; 18: 2526. https://doi.org/10.3390/ijms18122526Morizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. J. Dermatol. 2012; 39: 225–30. https://doi.org/10.1111/j.1346–8138.2011.01483.xMorizane S., Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. J. Dermatol. 2012; 39: 225–30. https://doi.org/10.1111/j.1346–8138.2011.01483.xMorizane S., Yamasaki K., Muhleisen B. et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR 9 ligands. J. Invest. Dermatol. 2012; 132: 135–43. https://doi.org/10.1038/jid.2011.259Morizane S., Yamasaki K., Muhleisen B. et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR 9 ligands. J. Invest. Dermatol. 2012; 132: 135–43. https://doi.org/10.1038/jid.2011.259Heidenreich R., Röcken M., Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. International Journal of Experimental Pathology, International Journal of Experimental Pathology. 2009; 90: 232–248. https://doi.org/10.1111/j.1365–2613.2009.00669.xHeidenreich R., Röcken M., Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. International Journal of Experimental Pathology, International Journal of Experimental Pathology. 2009; 90: 232–248. https://doi.org/10.1111/j.1365–2613.2009.00669.xWang X., Sun X., Qu X. et al. Overexpressed fbulin-3 contributes to the pathogenesis of psoriasis by promoting angiogenesis. Clin Exp Dermatol. 2018 [Epub ahead of print]. https://doi.org/10.1111/ ced.13720Wang X., Sun X., Qu X. et al. Overexpressed fbulin-3 contributes to the pathogenesis of psoriasis by promoting angiogenesis. Clin Exp Dermatol. 2018 [Epub ahead of print]. https://doi.org/10.1111/ ced.13720Kaliyadan F. The dermatoscopic auspitz sign. Indian Dermatol. Online J. 2018, 9, 290–291. https://doi.org/10.4103/idoj.IDOJ_309_17Kaliyadan F. The dermatoscopic auspitz sign. Indian Dermatol. Online J. 2018, 9, 290–291. https://doi.org/10.4103/idoj.IDOJ_309_17Sankar L., Arumugam D., Boj S., et al. Expression of angiogenic factors in psoriasis vulgaris. J Clin Diagn Res. 2017; 11 (3): EC23–EC27. https://doi.org/10.7860/JCDR/2017/23039.9525Sankar L., Arumugam D., Boj S., et al. Expression of angiogenic factors in psoriasis vulgaris. J Clin Diagn Res. 2017; 11 (3): EC23–EC27. https://doi.org/10.7860/JCDR/2017/23039.9525Namiecinska M., Marciniak K., Nowak J.Z. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig Med Dosw (Online). 2005; 59: 573–583.Namiecinska M., Marciniak K., Nowak J.Z. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig Med Dosw (Online). 2005; 59: 573–583.Malecic N., Young H. S. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia. Exp Dermatol. 2017; 26 (4): 299–304. https://doi.org/10.1111/exd.13310.Malecic N., Young H. S. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia. Exp Dermatol. 2017; 26 (4): 299–304. https://doi.org/10.1111/exd.13310.Holubar K., Fatović-Ferencić S. Papillary tip bleeding or the Auspitz phenomenon: A hero wrongly credited and a misnomer resolved. Journal of the American Academy of Dermatology. 48. 263–4. https://doi.org/10.1067/mjd.2003.89.Holubar K., Fatović-Ferencić S. Papillary tip bleeding or the Auspitz phenomenon: A hero wrongly credited and a misnomer resolved. Journal of the American Academy of Dermatology. 48. 263–4. https://doi.org/10.1067/mjd.2003.89.Veale D., Yanni G., Rogers S., L. et al. Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis & Rheumatism. 1993; Vol. 36, No. 7, pp. 893–900. https://doi.org/10.1002/art.1780360705Veale D., Yanni G., Rogers S., L. et al. Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis & Rheumatism. 1993; Vol. 36, No. 7, pp. 893–900. https://doi.org/10.1002/art.1780360705Reece R. J., Canete J. D., Parsons W. J. et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis and Rheumatism. 1999; Vol. 42, No. 7, pp. 1481–1484. https://doi.org/10.1002/1529–0131(199907)42:7<1481:: AID-ANR23>3.0.CO;2-EReece R. J., Canete J. D., Parsons W. J. et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis and Rheumatism. 1999; Vol. 42, No. 7, pp. 1481–1484. https://doi.org/10.1002/1529–0131(199907)42:7<1481:: AID-ANR23>3.0.CO;2-EPepper M.S. Manipulating angiogenesis: from basic science to the bedside. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; Vol. 17, No. 4, pp. 605–619. https://doi.org/10.1161/01.ATV.17.4.605Pepper M.S. Manipulating angiogenesis: from basic science to the bedside. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; Vol. 17, No. 4, pp. 605–619. https://doi.org/10.1161/01.ATV.17.4.605O’Reilly M.S., Boehm T., Shing Y. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; Vol. 88, No. 2, pp. 277–285. https://doi.org/10.1016/s0092–8674(00)81848–6O’Reilly M.S., Boehm T., Shing Y. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; Vol. 88, No. 2, pp. 277–285. https://doi.org/10.1016/s0092–8674(00)81848–6W. Risau. Mechanisms of angiogenesis. Nature. 1997; Vol. 386, No. 6626, pp. 671–674.W. Risau. Mechanisms of angiogenesis. Nature. 1997; Vol. 386, No. 6626, pp. 671–674.Gerkowicz A., Socha M., Pietrzak A., et al. The role of VEGF in psoriasis: an update. Acta Angiologica 2018; 24 (4): 134–140. https://doi.org/10.5603/AA.2018.0019Gerkowicz A., Socha M., Pietrzak A., et al. The role of VEGF in psoriasis: an update. Acta Angiologica 2018; 24 (4): 134–140. https://doi.org/10.5603/AA.2018.0019Tomanek R.J., Holifeld J.S., Reiter R.S. et al. Role of VEGF family members and receptors in coronary vessel formation. Dev. Dyn. 2002. 225. 233–240. https://doi.org/10.1002/dvdy.10158Tomanek R.J., Holifeld J.S., Reiter R.S. et al. Role of VEGF family members and receptors in coronary vessel formation. Dev. Dyn. 2002. 225. 233–240. https://doi.org/10.1002/dvdy.10158Melincovici C.S., Boşca A.B., Şuşman S., et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018; 59 (2): 455–467.Melincovici C.S., Boşca A.B., Şuşman S., et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018; 59 (2): 455–467.Kim, J., Kong, JS., Lee, S. et al. Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in rheumatoid arthritis. Exp Mol Med 2020. 52, 843–853. https://doi.org/10.1038/s12276–020–0443–8Kim, J., Kong, JS., Lee, S. et al. Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in rheumatoid arthritis. Exp Mol Med 2020. 52, 843–853. https://doi.org/10.1038/s12276–020–0443–8Young H.S., Kamaly-Asl I.D., et al. Genetic interaction between placenta growth factor (PGF) and vascular endothelial growth factor A (VEGFA) in psoriasis. Clinical and Experimental Dermatology. 2019. 45 (3). https://doi.org/10.1111/ced.14102Young H.S., Kamaly-Asl I.D., et al. Genetic interaction between placenta growth factor (PGF) and vascular endothelial growth factor A (VEGFA) in psoriasis. Clinical and Experimental Dermatology. 2019. 45 (3). https://doi.org/10.1111/ced.14102Xu M., Hua Y., Qi Y., Meng G., Yang S. Exogenous hydrogen sulphide supplement accelerates skin wound healing via oxidative stress inhibition and vascular endothelial growth factor enhancement. Exp Dermatol. 2019; 28 (7): 776–785. https://doi.org/10.1111/exd.13930Xu M., Hua Y., Qi Y., Meng G., Yang S. Exogenous hydrogen sulphide supplement accelerates skin wound healing via oxidative stress inhibition and vascular endothelial growth factor enhancement. Exp Dermatol. 2019; 28 (7): 776–785. https://doi.org/10.1111/exd.13930Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci. 2000; 24 Suppl 1: S78–S84. https://doi.org/10.1016/s0923–1811(00)00145–6Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci. 2000; 24 Suppl 1: S78–S84. https://doi.org/10.1016/s0923–1811(00)00145–6Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69 Suppl 3: 4–10. https://doi.org/10.1159/000088478Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69 Suppl 3: 4–10. https://doi.org/10.1159/000088478Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473 (7347): 298–307. https://doi.org/10.1038/nature10144Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473 (7347): 298–307. https://doi.org/10.1038/nature10144Honorati M.C., Cattini L., Facchini A. IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondro- cytes. Osteoarthritis Cartilage. 2004; 12(9): 683–691. https://doi.org/10.1016/j.joca.2004.05.009Honorati M.C., Cattini L., Facchini A. IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondro- cytes. Osteoarthritis Cartilage. 2004; 12(9): 683–691. https://doi.org/10.1016/j.joca.2004.05.009Hori R., Nakagawa T., Yamamoto N. et al. Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear. BMC Neurosci. 2010; 11: 35. https://doi.org/10.1186/1471–2202–11–35Hori R., Nakagawa T., Yamamoto N. et al. Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear. BMC Neurosci. 2010; 11: 35. https://doi.org/10.1186/1471–2202–11–35Yamazaki Y., Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. 2006; 10 (4): 515–527. https://doi.org/10.1007/s11030–006–9027–3Yamazaki Y., Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. 2006; 10 (4): 515–527. https://doi.org/10.1007/s11030–006–9027–3Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006; 39 (5): 469–478. https://doi.org/10.5483/bmbrep.2006.39.5.469Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006; 39 (5): 469–478. https://doi.org/10.5483/bmbrep.2006.39.5.469Neufeld G., Cohen T., Shraga N., Lange T., Kessler O., Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002; 12 (1): 13–19. https://doi.org/10.1016/s1050–1738(01)00140–2Neufeld G., Cohen T., Shraga N., Lange T., Kessler O., Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002; 12 (1): 13–19. https://doi.org/10.1016/s1050–1738(01)00140–2Marina M.E., Roman I.I., Constantin A.M., et al. VEGF involvement in psoriasis. Clujul Med. 2015; 88 (3): 247–252. https://doi.org/10.15386/cjmed-494Marina M.E., Roman I.I., Constantin A.M., et al. VEGF involvement in psoriasis. Clujul Med. 2015; 88 (3): 247–252. https://doi.org/10.15386/cjmed-494Veikkola T., Karkkainen M., Claesson-Welsh L., et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000. 60 (2): 203–212.Veikkola T., Karkkainen M., Claesson-Welsh L., et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000. 60 (2): 203–212.Herzog B., Pellet-Many C., Britton G. et al. VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell. 2011; 22 (15): 2766–2776. https://doi.org/10.1091/mbc.E09–12–1061Herzog B., Pellet-Many C., Britton G. et al. VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell. 2011; 22 (15): 2766–2776. https://doi.org/10.1091/mbc.E09–12–1061Parker M.W., Linkugel A.D., Goel H.L., et al. Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form. Structure. 2015; 23 (4):677–687. https://doi.org/10.1016/j.str.2015.01.018Parker M.W., Linkugel A.D., Goel H.L., et al. Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form. Structure. 2015; 23 (4):677–687. https://doi.org/10.1016/j.str.2015.01.018Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009; 29 (6): 789–791. https://doi.org/10.1161/ATVBAHA.108.179663Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009; 29 (6): 789–791. https://doi.org/10.1161/ATVBAHA.108.179663Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med. 2000; 6 (10): 1102–1103. https://doi.org/10.1038/80430Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med. 2000; 6 (10): 1102–1103. https://doi.org/10.1038/80430Lee S., Jilani S.M., Nikolova G.V., et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005; 169 (4): 681–691. https://doi.org/10.1083/jcb.200409115Lee S., Jilani S.M., Nikolova G.V., et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005; 169 (4): 681–691. https://doi.org/10.1083/jcb.200409115Baek J., Jang J. E., Kang C. M. et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000. 19, 4621–4631. https://doi.org/10.1038/sj.onc.1203814Baek J., Jang J. E., Kang C. M. et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000. 19, 4621–4631. https://doi.org/10.1038/sj.onc.1203814Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9 (6): 669–676. https://doi.org/10.1038/nm0603–669Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9 (6): 669–676. https://doi.org/10.1038/nm0603–669Kuzuya M., Ramos M.A., Kanda S., et al. VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor. Arterioscler Thromb Vasc Biol. 2001; 21 (5): 765–770. https://doi.org/10.1161/01.atv.21.5.765Kuzuya M., Ramos M.A., Kanda S., et al. VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor. Arterioscler Thromb Vasc Biol. 2001; 21 (5): 765–770. https://doi.org/10.1161/01.atv.21.5.765Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005; 65 (3): 550–563. https://doi.org/10.1016/j.cardiores.2004.12.002Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005; 65 (3): 550–563. https://doi.org/10.1016/j.cardiores.2004.12.002Yang J., Yan J., Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front. Immunol., 2018, Vol. 9, p. 978. https://doi.org/10.3389/fmmu.2018.00978Yang J., Yan J., Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front. Immunol., 2018, Vol. 9, p. 978. https://doi.org/10.3389/fmmu.2018.00978Voron T., Marcheteau E., Pernot S., Colussi O., Tartour E., Taieb J., Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol., 2014, Vol. 4, p. 70. https://doi.org/10.3389/fonc.2014.00070Voron T., Marcheteau E., Pernot S., Colussi O., Tartour E., Taieb J., Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol., 2014, Vol. 4, p. 70. https://doi.org/10.3389/fonc.2014.00070Detmar M., Brown L.F., Schön M.P., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998; 111 (1): 1–6. https://doi.org/10.1046/j.1523–1747.1998.00262.xDetmar M., Brown L.F., Schön M.P., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998; 111 (1): 1–6. https://doi.org/10.1046/j.1523–1747.1998.00262.xXia Y.P., Li B., Hylton D., et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003; 102 (1): 161–168. https://doi.org/10.1182/blood-2002–12–3793Xia Y.P., Li B., Hylton D., et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003; 102 (1): 161–168. https://doi.org/10.1182/blood-2002–12–3793Simonetti O., Lucarini G., Goteri G., et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol. 2006; 19 (4): 751–760. https://doi.org/10.1177/039463200601900405Simonetti O., Lucarini G., Goteri G., et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol. 2006; 19 (4): 751–760. https://doi.org/10.1177/039463200601900405Rashed H., El-Bary E.A. Immunohistochemical evaluation of VEGF, surviving, bcl-2 protein and iNOS in the pathogenesis of psoriasis. Egyptian Journal of Pathology. 2012; 32 (1): 91–98. https://doi.org/10.1097/01.xej.0000417556.36570.93.Rashed H., El-Bary E.A. Immunohistochemical evaluation of VEGF, surviving, bcl-2 protein and iNOS in the pathogenesis of psoriasis. Egyptian Journal of Pathology. 2012; 32 (1): 91–98. https://doi.org/10.1097/01.xej.0000417556.36570.93.Liew S.C., Das-Gupta E., Chakravarthi S., et al. Differential expression of the angiogenesis growth factors in psoriasis vulgaris. BMC Res Notes. 2012; 5: 201. https://doi.org/10.1186/1756–0500–5–201Liew S.C., Das-Gupta E., Chakravarthi S., et al. Differential expression of the angiogenesis growth factors in psoriasis vulgaris. BMC Res Notes. 2012; 5: 201. https://doi.org/10.1186/1756–0500–5–201Moustou A.E., Alexandrou P., Stratigos A.J., et al. Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment. An Bras Dermatol. 2014; 89 (6): 891–897. https://doi.org/10.1590/abd1806–4841.20143210Moustou A.E., Alexandrou P., Stratigos A.J., et al. Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment. An Bras Dermatol. 2014; 89 (6): 891–897. https://doi.org/10.1590/abd1806–4841.20143210Man X.Y., Yang X.H., Cai S.Q., et al. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med. 2006; 12 (7–8): 127–136. https://doi.org/10.2119/2006–00024Man X.Y., Yang X.H., Cai S.Q., et al. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med. 2006; 12 (7–8): 127–136. https://doi.org/10.2119/2006–00024Man X. Y., Yang X. H., Cai S. Q., et al. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med. 2008; 12 (2): 649–660. https://doi.org/10.1111/j.1582–4934.2007.00112.xMan X. Y., Yang X. H., Cai S. Q., et al. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med. 2008; 12 (2): 649–660. https://doi.org/10.1111/j.1582–4934.2007.00112.xJiang M., Li B., Zhang J., et al. Vascular endothelial growth factor driving aberrant keratin expression pattern contributes to the pathogenesis of psoriasis. Exp Cell Res. 2017; 360 (2): 310–319. https://doi.org/10.1016/j.yexcr.2017.09.021Jiang M., Li B., Zhang J., et al. Vascular endothelial growth factor driving aberrant keratin expression pattern contributes to the pathogenesis of psoriasis. Exp Cell Res. 2017; 360 (2): 310–319. https://doi.org/10.1016/j.yexcr.2017.09.021Flisiak I., Zaniewski P., Rogalska M., et al. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine. 2010; 52 (3): 225–229. https://doi.org/10.1016/j.cyto.2010.09.012Flisiak I., Zaniewski P., Rogalska M., et al. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine. 2010; 52 (3): 225–229. https://doi.org/10.1016/j.cyto.2010.09.012Meki AR, Al-Shobaili H. Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity. J Clin Lab Anal. 2014; 28 (6): 496–501. https://doi.org/10.1002/jcla.21717Meki AR, Al-Shobaili H. Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity. J Clin Lab Anal. 2014; 28 (6): 496–501. https://doi.org/10.1002/jcla.21717Andrys C., Borska L., Pohl D., et al. Angiogenic activity in patients with psoriasis is signifcantly decreased by Goeckerman’s therapy. Arch Dermatol Res. 2007; 298 (10): 479–483. https://doi.org/10.1007/s00403–006–0723–8Andrys C., Borska L., Pohl D., et al. Angiogenic activity in patients with psoriasis is signifcantly decreased by Goeckerman’s therapy. Arch Dermatol Res. 2007; 298 (10): 479–483. https://doi.org/10.1007/s00403–006–0723–8Akman A., Dicle O., Yilmaz F., et al. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photo-immunol Photomed. 2008; 24 (3): 123–127. https://doi.org/10.1111/j.1600–0781.2008.00349.xAkman A., Dicle O., Yilmaz F., et al. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVB. Photodermatol Photo-immunol Photomed. 2008; 24 (3): 123–127. https://doi.org/10.1111/j.1600–0781.2008.00349.xSudhesan A., Rajappa M., Chandrashekar L., et al. Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils. Hum Immunol. 2017; 78 (10): 657–663. https://doi.org/10.1016/j.humimm.2017.08.004Sudhesan A., Rajappa M., Chandrashekar L., et al. Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils. Hum Immunol. 2017; 78 (10): 657–663. https://doi.org/10.1016/j.humimm.2017.08.004Young H.S., Summers A.M., Read I.R., et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006; 126 (2): 453–459. https://doi.org/10.1038/sj.jid.5700096Young H.S., Summers A.M., Read I.R., et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006; 126 (2): 453–459. https://doi.org/10.1038/sj.jid.5700096Young H.S., Summers A.M., Bhushan M., et al. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004; 122 (1): 209–215. https://doi.org/10.1046/j.0022–202X.2003.22107.xYoung H.S., Summers A.M., Bhushan M., et al. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004; 122 (1): 209–215. https://doi.org/10.1046/j.0022–202X.2003.22107.xLi Y., Su J., Li F., et al. MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment. PLoS One. 2017; 12 (4): e0175459. https://doi.org/10.1371/journal.pone.0175459Li Y., Su J., Li F., et al. MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment. PLoS One. 2017; 12 (4): e0175459. https://doi.org/10.1371/journal.pone.0175459Zheng Y.Z., Chen C.F., Jia L.Y., et al. Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris. Oncotarget. 2017; 8 (31): 51288–51295. https://doi.org/10.18632/oncotarget.17260Zheng Y.Z., Chen C.F., Jia L.Y., et al. Correlation between microRNA-143 in peripheral blood mononuclear cells and disease severity in patients with psoriasis vulgaris. Oncotarget. 2017; 8 (31): 51288–51295. https://doi.org/10.18632/oncotarget.17260Xu Y, Ji Y, Lan X, et al. miR203 contributes to IL17induced VEGF secretion by targeting SOCS3 in keratinocytes. Mol Med Rep. 2017; 16 (6): 8989–8996. https://doi.org/10.3892/mmr.2017.7759Xu Y, Ji Y, Lan X, et al. miR203 contributes to IL17induced VEGF secretion by targeting SOCS3 in keratinocytes. Mol Med Rep. 2017; 16 (6): 8989–8996. https://doi.org/10.3892/mmr.2017.7759Fearon U., Reece R., Smith J. et al. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Annals of the New York Academy of Sciences. 1999; Vol. 878, pp. 619–621. https://doi.org/10.1111/j.1749–6632.1999.tb07743.xFearon U., Reece R., Smith J. et al. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Annals of the New York Academy of Sciences. 1999; Vol. 878, pp. 619–621. https://doi.org/10.1111/j.1749–6632.1999.tb07743.xYamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol. 2013; 2013: 630620. https://doi.org/10.1155/2013/630620Yamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol. 2013; 2013: 630620. https://doi.org/10.1155/2013/630620Ballara S., Taylor P. C., Reusch P., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001; 44 (9): 2055–2064. https://doi.org/10.1002/1529–0131(200109)44:9<2055:: AID-ART355>3.0.CO;2–2Ballara S., Taylor P. C., Reusch P., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001; 44 (9): 2055–2064. https://doi.org/10.1002/1529–0131(200109)44:9<2055:: AID-ART355>3.0.CO;2–2Ballara S.C., Miotla J.M., Paleolog E.M. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol. 1999; 80 (5): 235–250. https://doi.org/10.1046/j.1365–2613.1999.00129.xBallara S.C., Miotla J.M., Paleolog E.M. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol. 1999; 80 (5): 235–250. https://doi.org/10.1046/j.1365–2613.1999.00129.xPrzepiera-Będzak H., Fischer K., Brzosko M. Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome. Pol Arch Med Wewn. 2013; 123 (6): 297–302. https://doi.org/10.20452/pamw.1772Przepiera-Będzak H., Fischer K., Brzosko M. Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome. Pol Arch Med Wewn. 2013; 123 (6): 297–302. https://doi.org/10.20452/pamw.1772Barile S., Medda E., Nisticò L., et al. Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol. 2006; 15 (5): 368–376. https://doi.org/10.1111/j.0906–6705.2006.00416.xBarile S., Medda E., Nisticò L., et al. Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol. 2006; 15 (5): 368–376. https://doi.org/10.1111/j.0906–6705.2006.00416.xButt C., Lim S., Greenwood C., Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord. 2007; 8: 1. https://doi.org/10.1186/1471–2474–8–1Butt C., Lim S., Greenwood C., Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord. 2007; 8: 1. https://doi.org/10.1186/1471–2474–8–1Han S.W., Kim G.W., Seo J.S. et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology. 2004; Vol. 43, No. 9, pp. 1173–1177. https://doi.Han S.W., Kim G.W., Seo J.S. et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology. 2004; Vol. 43, No. 9, pp. 1173–1177. https://doi.org/10.1093/rheumatology/keh281org/10.1093/rheumatology/keh281Veale D.J., Ritchlin C., FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005; 64 Suppl 2 (Suppl 2): ii26–ii29. https://doi.org/10.1136/ard.2004.031740Veale D.J., Ritchlin C., FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005; 64 Suppl 2 (Suppl 2): ii26–ii29. https://doi.org/10.1136/ard.2004.031740Akman A., Yilmaz E., Mutlu H., et al. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009; 34 (5): e202–e204. https://doi.org/10.1111/j.1365–2230.2008.02991.xAkman A., Yilmaz E., Mutlu H., et al. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009; 34 (5): e202–e204. https://doi.org/10.1111/j.1365–2230.2008.02991.xDatta-Mitra A., Riar N.K., Raychaudhuri S.P. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol. 2014 Nov; 59 (6): 632. https://doi.org/10.4103/0019–5154.143574Datta-Mitra A., Riar N.K., Raychaudhuri S.P. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol. 2014 Nov; 59 (6): 632. https://doi.org/10.4103/0019–5154.143574Belasco J., Wei N. Psoriatic Arthritis: What is Happening at the Joint? Rheumatol Ther. 2019; 6 (3): 305–315. https://doi.org/10.1007/s40744–019–0159–1Belasco J., Wei N. Psoriatic Arthritis: What is Happening at the Joint? Rheumatol Ther. 2019; 6 (3): 305–315. https://doi.org/10.1007/s40744–019–0159–1Cantatore F. P., Maruotti N., Corrado A., Ribatti D. Anti-angiogenic effects of biotechnological therapies in rheumatic diseases. Biologics. 2017; 11: 123–128. https://doi.org/10.2147/BTT.S143674Cantatore F. P., Maruotti N., Corrado A., Ribatti D. Anti-angiogenic effects of biotechnological therapies in rheumatic diseases. Biologics. 2017; 11: 123–128. https://doi.org/10.2147/BTT.S143674

The authors declare that there are no conflicts of interest present.